8-K: Silexion Therapeutics Retires Convertible Note with EarlyBirdCapital

Silexion Therapeutics Corp. settles a $1.25 million convertible promissory note with EarlyBirdCapital, Inc. through a combination of cash payment, share issuance, and potential settlement amount.

Summary

• Silexion Therapeutics Corp. entered into an agreement with EarlyBirdCapital, Inc. (EBC) to retire a convertible promissory note dated August 15, 2024.
• The original note amount was $1,250,000.
• As of March 13, 2025, the outstanding principal and interest was $880,202.20.
• The agreement involves a $400,000 cash payment (plus $15,000 in legal expenses) from Silexion to EBC.
• Silexion will issue 277,777 ordinary shares to EBC, with the conversion amount based on the net proceeds EBC receives from selling these shares.
• A final settlement amount will be calculated based on the difference between the outstanding amount, the cash payment, and the net proceeds from the share sales.
• If the net proceeds and cash payment exceed the outstanding amount, EBC will refund the excess to Silexion.
• The EBC Shares have been issued pursuant to an effective registration statement of the Company on Form S-1 (Registration No. 333-282556) as required by the Convertible Note.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While retiring debt is generally positive, the dilution of shares is a negative aspect. The overall impact depends on the company's future performance and how effectively it uses the freed-up capital.

Positives

• Silexion Therapeutics retires a convertible note, removing a potential debt obligation.
• The agreement involves a combination of cash and share issuance, potentially preserving cash reserves.
• The issuance of shares could increase the company's shareholders equity.

Negatives

• The company is using cash to settle part of the debt, reducing its cash reserves.
• Issuing shares dilutes existing shareholders' ownership.

Risks

• The value EarlyBirdCapital receives from selling the 277,777 shares depends on market conditions.
• If the share price declines significantly, EarlyBirdCapital may receive less than anticipated, potentially affecting the final settlement amount.
• A Payment Default would result in the Note remaining outstanding and in full force and effect, including provisions related to penalty interest.

Future Outlook

The agreement outlines the steps for full settlement of the note balance and retirement of the note, contingent on the sale of shares and final settlement calculations.

Management Comments

• The document includes signatures from Ilan Hadar, Chief Executive Officer, and Mirit Horenshtein Hadar, Chief Financial Officer, of Silexion Therapeutics Corp.

Industry Context

This type of agreement is common for companies seeking to manage their debt obligations and improve their balance sheets. Converting debt to equity can be a strategic move, but it also carries the risk of diluting existing shareholders.

Comparison to Industry Standards

• Similar convertible note settlements are often seen in the biotech industry, where companies may use this method to manage short-term debt.
• Comparable companies might include smaller biotech firms that rely on convertible notes for funding and later convert them to equity.
• The terms of the agreement, such as the conversion price and settlement calculations, are typical for these types of transactions.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company's financial stability may improve by reducing debt obligations.
• EarlyBirdCapital benefits from the cash payment and potential profit from selling the shares.

Next Steps

• EarlyBirdCapital will sell the 277,777 ordinary shares in broker transactions on the Nasdaq Stock Market.
• EarlyBirdCapital will provide a Note Shares Sales Report to Silexion Therapeutics.
• Silexion Therapeutics will calculate and pay the Settlement Amount to EarlyBirdCapital (or vice versa).
• EarlyBirdCapital will return the original signed Note to Silexion Therapeutics.

Key Dates